[CAS NO. 24150-24-1] Terameprocol
PRODUCTS SPECIFICATIONS [24150-24-1]
DESCRIPTION [24150-24-1]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 358.47 |
| Molecular Formula | C22H30O4 |
| SMILES | COC1=CC(C[C@H](C)[C@H](C)CC2=CC=C(OC)C(OC)=C2)=CC=C1OC |
Summary
Terameprocol is a synthetic derivative of Nordihydroguaiaretic acid and a non-selective lipoxygenase inhibitor. Terameprocol has antiviral and antitumor effects [1] [2] [3] .
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT00259818 | Erimos Pharmaceuticals |
Cancer
|
December 2005 | Phase 1 |
| NCT00664586 | Erimos Pharmaceuticals |
Refractory Solid Tumors|Lymphoma
|
May 2007 | Phase 1 |
| NCT00154089 | Erimos Pharmaceuticals|University of Maryland, Baltimore County|Planned Parenthood Delaware (Wilmington, DE) |
Cervical Intraepithelial Neoplasia
|
November 2004 | Phase 1|Phase 2 |
| NCT00664677 | Erimos Pharmaceuticals |
Leukemias|Acute Myeloid Leukemia (AML)|Acute Lymphocytic Leukemia (ALL)|Adult T Cell Leukemia (ATL)|Chronic Myeloid Leukemia (CML-BP)|Chronic Lymphocytic Leukemia (CLL)|Myelodysplastic Syndrome (MDS)|Chronic Myelomonocytic Leukemia (CMML)
|
August 2007 | Phase 1 |
| NCT00404248 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Brain and Central Nervous System Tumors
|
January 2007 | Phase 1|Phase 2 |
| NCT02575794 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Erimos Pharmaceuticals|National Cancer Institute (NCI) |
High Grade Glioma (III or IV)
|
May 3, 2018 | Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 100 mg/mL ( 278.96 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.7896 mL | 13.9482 mL | 27.8963 mL |
| 5 mM | 0.5579 mL | 2.7896 mL | 5.5793 mL |
| 10 mM | 0.2790 mL | 1.3948 mL | 2.7896 mL |
References
- [1] Hwu JR, et al. Antiviral activities of methylated nordihydroguaiaretic acids. 1. Synthesis, structure identification, and inhibition of tat-regulated HIV transactivation. J Med Chem. 1998 Jul 30;41(16):2994-3000.
- [2] Chen H, et al. Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA. J Med Chem. 1998 Jul 30;41(16):3001-7.
- [3] Park R, et al. Systemic treatment with tetra-O-methyl nordihydroguaiaretic acid suppresses the growth of human xenograft tumors. Clin Cancer Res. 2005 Jun 15;11(12):4601-9.
